[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350377-105":59,"doc-detail-350377-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cd4-t-cells-sensitize-quasimesenchymal-breast-tumors-lacking-cd73-to-anti-ctla4-immune-checkpoint-blockade-therapy","CD4 + T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy","","Although immune checkpoint blockade (ICB) can yield strong responses in some cancers, breast tumors often remain unresponsive. Epithelial–mesenchymal plasticity (EMP) fosters an immunosuppressive tumor microenvironment that drives resistance. Targeting CD73 fully sensitizes quasi-mesenchymal (qM) breast tumors to anti-CTLA4 therapy, yet the sensitization mechanism was unclear. The study shows CD73 targeting sensitizes qM tumors via a CD4+ T cell–dependent pathway, and EMP increases intrinsic CD73 in human triple-negative breast cancers, supporting translational strategies and predictive criteria using cancer plasticity, CD73, and CD4+ T cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cd4-t-cells-sensitize-quasimesenchymal-breast-tumors-lacking-cd73-to-anti-ctla4-immune-checkpoint-blockade-therapy/350377/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cd4-t-cells-sensitize-quasimesenchymal-breast-tumors-lacking-cd73-to-anti-ctla4-immune-checkpoint-blockade-therapy/350377.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are breast tumors often resistant to immune checkpoint blockade (ICB) therapy?","Question",{"text":112,"@type":113},"Breast tumors are largely unresponsive to ICB, and epithelial–mesenchymal plasticity (EMP) supports an immunosuppressive tumor microenvironment that contributes to resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does targeting CD73 affect quasimesenchymal (qM) breast tumors and anti-CTLA4 therapy?",{"text":117,"@type":113},"Targeting CD73 completely sensitizes qM breast tumors to anti-CTLA4 immune checkpoint blockade, mediated in a CD4+ T cell–dependent manner.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does EMP play regarding CD73 expression in human triple-negative breast cancers?",{"text":121,"@type":113},"EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers, linking phenotypic plasticity to immunotherapy responsiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350377,1790313561,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-26-0304](https://doi.org/10.1158/2767-9764.CRC-26-0304)  OPEN ACCESS  \nCD4 + T Cells Sensitize Quasimesenchymal  Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy  \nShiney Chandraganti1, Caitlyn Sams1, Sarthak Sahoo2, Brian Feng1, Isabel O’Connell1, Lynna Li1, Sunita Nepal1, Siddhartha Pulukuri1, Kimaya Bakhle1, Prathapan Thiru3, Corina Simian3,4, Viviana Maymi5, Brian D. Rudd5, George W. Bell3, Stephen Hatfield6, Mohit Kumar Jolly2, and Anushka Dongre1  \n􀀶  \nABSTRACT  \nAlthough immune checkpoint blockade (ICB) therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial–mesenchymal plasticity (EMP) leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal (qM) breast tumors to anti-CTLA4 ICB therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in qM breast tumors sensitizes them to anti-CTLA4 ICB therapy in a CD4+ T cell– dependent manner. Moreover, EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers.  \nGiven the ability of qM cancer cells to metastasize and resist multiple therapies, these findings can instruct the formation of translational strategies for the treatment of human breast cancers. These findings also bring to the forefront the attractive possibility of utilizing the phenotypic plasticity of cancer cells along with CD73 and CD4+ T cells as a predictive criterion for immunotherapy responsiveness.  \nSignificance: EMP enables metastasis and drives resistance to multiple treatment regimens. Our work underscores the possibility of utilizing CD4+ T cells, CD73, and cancer plasticity as predictive criteria for responsiveness to immunotherapy.  \nIntroduction  \nThe use of immune checkpoint blockade (ICB) therapies, which harness the immune system to kill cancer cells, has revolutionized cancer treatment by creating durable clinical responses ( 1) . However, whereas melanomas and lung cancers mount proficient responses to these therapies, certain other cancer types, such as breast carcinomas, are still largely unresponsive (2–5) . It is therefore critical that we drastically improve the curative potential of  \n1Department of Biomedical and Translational Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York. 2Department of Bioengineering, Indian Institute of Science, Bangalore, India. 3Whitehead Institute for Biomedical Research, Cambridge, Massachusetts. 4Institute for Plant-Human Interface, Northeastern University, Boston, Massachusetts. 5Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York. 6New England Inflammation and Tissue Protection Institute, Northeastern University, Boston, Massachusetts.  \nCorresponding Author: Anushka Dongre, Department of Biomedical and Translational Sciences, Cornell University, T7-012A, 930 Campus Road, Ithaca, NY 14853. E-mail: [ad789@cornell.edu](ad789@cornell.edu)  \ndoi: 10.1158/2767-9764.CRC-26-0304  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the American Association for Cancer Research  \nthese therapies by understanding the mechanisms by which breast cancer cells mount resistance to immunotherapy.  \nEpithelial–mesenchymal plasticity (EMP), which converts epithelial cells tomesenchymal derivatives, endows cancer cells with many traits associated with high-grade malignancies. This includes their ability to metastasize to distant organ sites, acquire tumor-initiating abilities, and mount resistance to chemotherapies (6–9) . In fact, EMP is a highly dynamic process which often gives rise to a spectrum of partial or quasi-mese","cbCainubgBJiDehB","https://ap.wps.com/l/cbCainubgBJiDehB","pdf",22662343,17,"English","# Abstract\n# Introduction","[{\"question\":\"Why are breast tumors often resistant to immune checkpoint blockade (ICB) therapy?\",\"answer\":\"Breast tumors are largely unresponsive to ICB, and epithelial–mesenchymal plasticity (EMP) supports an immunosuppressive tumor microenvironment that contributes to resistance.\"},{\"question\":\"How does targeting CD73 affect quasimesenchymal (qM) breast tumors and anti-CTLA4 therapy?\",\"answer\":\"Targeting CD73 completely sensitizes qM breast tumors to anti-CTLA4 immune checkpoint blockade, mediated in a CD4+ T cell–dependent manner.\"},{\"question\":\"What role does EMP play regarding CD73 expression in human triple-negative breast cancers?\",\"answer\":\"EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers, linking phenotypic plasticity to immunotherapy responsiveness.\"}]","CD4 + T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy | PDF",1790088774,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/236075a7bbe7a2da86474bca39e7c041.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/669d66a442cdcad22e917953d592e993.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be2805611bbffead9ef3cb26c2291f6f.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cb4fe492e24e283f7250327ba9f95ac.webp",980,1259]